MedTrace Logo

Safety, Biomarker Study of RL-007 in Subjects With Schizophrenia

NCT04822883 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2022-04-27

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and effects on electrical activity in the brain of an investigational drug (RL-007) for improving cognition in patients with schizophrenia

Conditions

Interventions

DRUG

RL-007

Cohorts are 10 mg, 20 mg, 40 mg, and 80 mg with TID dosing

DRUG

RL-007 Matching Placebo

Cohorts are 10 mg, 20 mg, 40 mg, and 80 mg with TID dosing

Sponsors & Collaborators

  • Recognify Life Sciences

    lead INDUSTRY

Principal Investigators

  • David Walling, PhD · Collaborative Neuroscience Research

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-26
Primary Completion
2021-10-28
Completion
2021-10-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04822883 on ClinicalTrials.gov